

# Anat Naschitz

**Anat Naschitz is an investor and a creator – of funds and companies.**

Currently she is founder and CEO of 9xc (stealth) and a Venture Partner at OrbiMed.

Anat co-founded and co-led OrbiMed Israel, raising 2 funds with \$529m under management. OrbiMed is a preeminent global healthcare investment firm with ~\$20 billion under management across public and private asset classes.

Anat serves on the boards of biotech, digital health and medical device companies, some of which she either founded or nurtured from an early stage. Current examples include Tyto, a telemedicine device platform in which she invested early and saw through notable success; ForSight Vision 6, developing an Accommodating IntraOcular Lens under a Strategic agreement; Azura, in the clinic with novel therapeutics for prevalent ophthalmology indications; and MDClone, commercializing novel analytics and synthetic technology which enables immediate querying and sharing of healthcare data. Until recently, Anat served on the board of 89bio (Nasdaq:ETNB), a biotech company she co-founded as a pharma spinout and helped take public 18 months later.

In her 25 years in the healthcare space, Anat has worked with companies of all sizes, including major pharmaceutical companies on the one hand and nascent biotechs on the other.

Previously Anat created, invested in and advised companies across the entire healthcare spectrum in terms of stage and subject matter. She was an Associate Partner with McKinsey in London, where she managed strategy and M&A projects for senior management of the world's preeminent pharmaceutical and biotechnology companies. Among other accomplishments, Anat led pharmaceutical spinout work resulting in the creation of European biotech companies valued at billions of dollars. Post McKinsey Anat joined Apax Partners, where she focused on life sciences investments. She earned her M.B.A. at INSEAD and her LL.B. at Tel Aviv University.